Rosemary Dziak
Rosemary Dziak has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Andrew W. Barone
Department of Oral Biology, University at Buffalo, State University of New York, 3435 Main Street, Buffalo 14216-3942, NY, USA
2 shared publicationsGabriela Fernandes
Department of Oral Biology, University at Buffalo, State University of New York, 3435 Main Street, Buffalo 14216-3942, NY, USA
2 shared publications- Adi Alghanem
King Fahad Medical City, Makkah Al Mukarramah Branch Rd., As Sulimaniyah, Riyadh 11525, Saudi Arabia
1 shared publication Andrew Barone
1 shared publicationB.M Yang
1 shared publicationB.W Leung
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by Sci Forschen, Inc. in International Journal of Dentistry and Oral Health
- Vol. 6 (4)
Dose-Related Effects of Melatonin on Human Osteoblastic Cells via in vitro Controlled Release from Nanoscale Calcium Sulfate
Introduction: Engineering biodegradable scaffolds for bone regeneration in osseous defects is an attractive alternative to harvesting grafts from living tissues.
- 1 January 2020
- Published by Sci Forschen, Inc. in International Journal of Dentistry and Oral Health
- Vol. 6 (4)
Open AccessDose-Related Effects of Melatonin on Human Osteoblastic Cells via in vitro Controlled Release from Nanoscale Calcium Sulfate
Introduction: Engineering biodegradable scaffolds for bone regeneration in osseous defects is an attractive alternative to harvesting grafts from living tissues.
- Open Access
- 10 August 2018
- Published by Gratis Open Access Publishers LLC in Journal of Bone Biology and Osteoporosis
- Vol. 4 (1) , 59-67
Effects of Chromeceptin on Insulin-like Growth Factor II in Human Osteoblastic and Osteosarcoma Cells
The insulin-like growth factor system is a complex regulatory system of insulin-like growth factors I and II (IGF-I and IGF-II) as well as their cell surface receptors and a family of insulin growth factor binding proteins (IGF-BPs). Despite extensive research on the IGF system in skeletal tissue, there is still not a complete understanding particularly of the role of IGF-II in the regulation of normal and pathological osseous cells in human skeletal biology. The purpose of this study was to further delineate the possible involvement of IGF-II in the regulation of human normal calvarial osteoblasts and G292 human osteosarcoma cellular activity using exogenously added IGF-II as well as a drug, Chromeceptin that has been shown in some other cellular systems to down regulate endogenous IGF-II levels.The results presented here show a similar dose dependent effect of Chromeceptin on inhibition of endogenous IGF-II levels (measured with an immunoassay) and cellular activity (measured with the MTT assay) in both the normal and osteosarcoma cells while small significant increases in activity with exogenously added IGF-II were observed only in the osteosarcoma cells. Moreover, IGF-BP1 levels (measured with an immunoassay) were shown to significantly increase in the G292 cells in a similar manner previously reported in other cell systems with only minor non-significant effects of exogenously added IGF-BP1 in the osteosarcoma cells studied here. These studies suggest that endogenous IGF-II is a critical regulator of activity in both normal and osteosarcoma cells and Chromeceptin can be an effective pharmacological agent for further studies on the role of the growth factor in human skeletal systems.
- 10 August 2018
- Published by Gratis Open Access Publishers LLC in Journal of Bone Biology and Osteoporosis
- Vol. 4 (1) , 59-67
Open AccessEffects of Chromeceptin on Insulin-like Growth Factor II in Human Osteoblastic and Osteosarcoma Cells
The insulin-like growth factor system is a complex regulatory system of insulin-like growth factors I and II (IGF-I and IGF-II) as well as their cell surface receptors and a family of insulin growth factor binding proteins (IGF-BPs). Despite extensive research on the IGF system in skeletal tissue, there is still not a complete understanding particularly of the role of IGF-II in the regulation of normal and pathological osseous cells in human skeletal biology. The purpose of this study was to further delineate the possible involvement of IGF-II in the regulation of human normal calvarial osteoblasts and G292 human osteosarcoma cellular activity using exogenously added IGF-II as well as a drug, Chromeceptin that has been shown in some other cellular systems to down regulate endogenous IGF-II levels.The results presented here show a similar dose dependent effect of Chromeceptin on inhibition of endogenous IGF-II levels (measured with an immunoassay) and cellular activity (measured with the MTT assay) in both the normal and osteosarcoma cells while small significant increases in activity with exogenously added IGF-II were observed only in the osteosarcoma cells. Moreover, IGF-BP1 levels (measured with an immunoassay) were shown to significantly increase in the G292 cells in a similar manner previously reported in other cell systems with only minor non-significant effects of exogenously added IGF-BP1 in the osteosarcoma cells studied here. These studies suggest that endogenous IGF-II is a critical regulator of activity in both normal and osteosarcoma cells and Chromeceptin can be an effective pharmacological agent for further studies on the role of the growth factor in human skeletal systems.
- Open Access
- 1 January 2018
- Published by Taylor & Francis in Cogent Biology
- Vol. 4 (1)
Effects of alendronate and interferon-γ on bone cancer cells in vitro
Bisphosphonates are used to reduce pathological osteolysis in bone cancer patients. In addition to direct effects on tumor cells, these drugs may also alter the production of immune cell factors within the tumor microenvironment. Interferon-γ (IFN-γ) represents one such factor whose production by T lymphocytes is increased following bisphosphonate treatment. This study characterized the effects of alendronate (ALN), an aminobisphosphonate, and IFN-γ on viability, maturation, and osteoclastic factor production in human G292 osteosarcoma cells. Viability was assessed with a colorimetric assay; maturation by alkaline phosphatase (ALP) and mineralization via alizarin red. Receptor activator of nuclear factor kappa-Β ligand (RANKL) and monocyte chemoattractant protein-1 (MCP-1) production were quantified with ELISAs. ALN (5 nM) had no effect on viability. IFN-γ (1,000 U/mL) decreased this parameter alone and in the presence of ALN. ALN had a transient inhibitory effect on ALP. While IFN-γ increased this parameter, ALN inhibited this effect. Whereas ALN and IFN-γ each decreased RANKL, cotreatment with IFN-γ lessened the inhibitory effect of ALN. ALN decreased MCP-1 and attenuated IFN-γ induced increases. These studies suggest that bisphosphonates have direct effects on bone tumor cells and on the actions of cytokines in the tumor microenvironment and provide a basis for optimization of bone cancer therapy.
- 1 January 2018
- Published by Taylor & Francis in Cogent Biology
- Vol. 4 (1)
Open AccessEffects of alendronate and interferon-γ on bone cancer cells in vitro
Bisphosphonates are used to reduce pathological osteolysis in bone cancer patients. In addition to direct effects on tumor cells, these drugs may also alter the production of immune cell factors within the tumor microenvironment. Interferon-γ (IFN-γ) represents one such factor whose production by T lymphocytes is increased following bisphosphonate treatment. This study characterized the effects of alendronate (ALN), an aminobisphosphonate, and IFN-γ on viability, maturation, and osteoclastic factor production in human G292 osteosarcoma cells. Viability was assessed with a colorimetric assay; maturation by alkaline phosphatase (ALP) and mineralization via alizarin red. Receptor activator of nuclear factor kappa-Β ligand (RANKL) and monocyte chemoattractant protein-1 (MCP-1) production were quantified with ELISAs. ALN (5 nM) had no effect on viability. IFN-γ (1,000 U/mL) decreased this parameter alone and in the presence of ALN. ALN had a transient inhibitory effect on ALP. While IFN-γ increased this parameter, ALN inhibited this effect. Whereas ALN and IFN-γ each decreased RANKL, cotreatment with IFN-γ lessened the inhibitory effect of ALN. ALN decreased MCP-1 and attenuated IFN-γ induced increases. These studies suggest that bisphosphonates have direct effects on bone tumor cells and on the actions of cytokines in the tumor microenvironment and provide a basis for optimization of bone cancer therapy.
- 1 September 2017
- Published by Elsevier in Dental Materials
- Vol. 33 (9) , e336-e347
Biocompatibility and bond degradation of poly-acrylic acid coated copper iodide-adhesives
- 1 September 2017
- Published by Elsevier in Dental Materials
- Vol. 33 (9) , e336-e347
Biocompatibility and bond degradation of poly-acrylic acid coated copper iodide-adhesives
- Open Access
- 1 January 2017
- Published by Taylor & Francis in Cogent Biology
- Vol. 3 (1) , 1288335
The effect of ascorbic acid on bone cancer cells in vitro
Ascorbic acid (Vitamin C) has long been known for its anti-cancer properties and in the present study the effects of ascorbic acid (AsA) on osteogenic differentiation, apoptosis, and signaling pathways of the human G29 osteosarcoma cell line were studied. The expression of Runt-related transcription factor-2 (RUNX2) and osteocalcin genes were evaluated by real-time polymerase chain reaction (PCR). Osteoblastic maturation was assessed with alkaline phosphatase activity and mineralization with alizarin red deposition, and apoptosis with a caspase-2 apoptotic assay as well as the cell viability via the cytotoxicity assay. The possible role of the MAP kinase pathway (p44/42, p38, and p-JNK signaling pathway) was also studied. Our results showed that RUNX2 and osteocalcin gene expression, mineralization, cell viability, and metabolic activity levels were increased in cells treated with low concentrations of AsA with respect to untreated cells. At higher concentrations, AsA resulted in decreases in these parameters and induced apoptosis of the G292 osteosarcoma cells via downregulation of the MAPK pathway. The findings presented here support the ability of AsA to modulate the viability and differentiation of the G292 type of bone cancer cell with increases or decreases depending on the AsA concentration suggesting a need for further evaluation of the possible use of this vitamin in the regulation of bone cell cancer growth.
- 1 January 2017
- Published by Taylor & Francis in Cogent Biology
- Vol. 3 (1) , 1288335
Open AccessThe effect of ascorbic acid on bone cancer cells in vitro
Ascorbic acid (Vitamin C) has long been known for its anti-cancer properties and in the present study the effects of ascorbic acid (AsA) on osteogenic differentiation, apoptosis, and signaling pathways of the human G29 osteosarcoma cell line were studied. The expression of Runt-related transcription factor-2 (RUNX2) and osteocalcin genes were evaluated by real-time polymerase chain reaction (PCR). Osteoblastic maturation was assessed with alkaline phosphatase activity and mineralization with alizarin red deposition, and apoptosis with a caspase-2 apoptotic assay as well as the cell viability via the cytotoxicity assay. The possible role of the MAP kinase pathway (p44/42, p38, and p-JNK signaling pathway) was also studied. Our results showed that RUNX2 and osteocalcin gene expression, mineralization, cell viability, and metabolic activity levels were increased in cells treated with low concentrations of AsA with respect to untreated cells. At higher concentrations, AsA resulted in decreases in these parameters and induced apoptosis of the G292 osteosarcoma cells via downregulation of the MAPK pathway. The findings presented here support the ability of AsA to modulate the viability and differentiation of the G292 type of bone cancer cell with increases or decreases depending on the AsA concentration suggesting a need for further evaluation of the possible use of this vitamin in the regulation of bone cell cancer growth.
- Open Access
- 21 September 2016
- Published by Herald Scholarly Open Access in Cell Biology & Cell Metabolism
- Vol. 3 (1) , 1-7
Effects of Verapamil on Bone Cancer Cells in vitro
Herald Scholarly Open Access publishes peer-reviewed scientific research which provides an immediate free access to articles. Herald Scholarly Open Access is publishing articles in 47 peer-reviewed Open Access journals in Biology, Medicine and Clinical sciences.
- 21 September 2016
- Published by Herald Scholarly Open Access in Cell Biology & Cell Metabolism
- Vol. 3 (1) , 1-7
Open AccessEffects of Verapamil on Bone Cancer Cells in vitro
Herald Scholarly Open Access publishes peer-reviewed scientific research which provides an immediate free access to articles. Herald Scholarly Open Access is publishing articles in 47 peer-reviewed Open Access journals in Biology, Medicine and Clinical sciences.
- 29 June 2016
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 22 (13-14) , 928-939
Hybrid Biomaterial with Conjugated Growth Factors and Mesenchymal Stem Cells for Ectopic Bone Formation
Bone is a highly vascularized tissue and efficient bone regeneration requires neovascularization, especially for critical-sized bone defects. We developed a novel hybrid biomaterial comprising nanocalcium sulfate (nCS) and fibrin hydrogel to deliver mesenchymal stem cells (MSCs) and angiogenic factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor 9 (FGF9), to promote neovascularization and bone formation. MSC and growth factor(s)-loaded scaffolds were implanted subcutaneously into mice to examine their angiogenic and osteogenic potential. Micro CT, alkaline phosphatase activity assay, and histological analysis were used to evaluate bone formation, while immunohistochemistry was employed to assess neovessel formation. The presence of fibrin preserved the nCS scaffold structure and promoted de novo bone formation. In addition, the presence of bone morphogenic protein 2-expressing MSC in nCS and fibrin hydrogels improved bone regeneration significantly. While FGF9 alone had no significant effect, the combination FGF9 and VEGF conjugated in fibrin enhanced neovascularization and bone formation more than 4-fold compared to nCS with MSC. Overall, our results suggested that the combination of nCS (to support bone formation) with a fibrin-based VEGF/FGF9 release system (support vascular formation) is an innovative and effective strategy that significantly enhanced ectopic bone formation in vivo .
- 29 June 2016
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 22 (13-14) , 928-939
Hybrid Biomaterial with Conjugated Growth Factors and Mesenchymal Stem Cells for Ectopic Bone Formation
Bone is a highly vascularized tissue and efficient bone regeneration requires neovascularization, especially for critical-sized bone defects. We developed a novel hybrid biomaterial comprising nanocalcium sulfate (nCS) and fibrin hydrogel to deliver mesenchymal stem cells (MSCs) and angiogenic factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor 9 (FGF9), to promote neovascularization and bone formation. MSC and growth factor(s)-loaded scaffolds were implanted subcutaneously into mice to examine their angiogenic and osteogenic potential. Micro CT, alkaline phosphatase activity assay, and histological analysis were used to evaluate bone formation, while immunohistochemistry was employed to assess neovessel formation. The presence of fibrin preserved the nCS scaffold structure and promoted de novo bone formation. In addition, the presence of bone morphogenic protein 2-expressing MSC in nCS and fibrin hydrogels improved bone regeneration significantly. While FGF9 alone had no significant effect, the combination FGF9 and VEGF conjugated in fibrin enhanced neovascularization and bone formation more than 4-fold compared to nCS with MSC. Overall, our results suggested that the combination of nCS (to support bone formation) with a fibrin-based VEGF/FGF9 release system (support vascular formation) is an innovative and effective strategy that significantly enhanced ectopic bone formation in vivo .
- 5 September 2013
- Published by Taylor & Francis in Immunological Investigations
- Vol. 42 (7) , 510-518
The role of sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) in regulation of osteoclastic and osteoblastic cells
The bioactive lipid molecules, sphingosine-1-phosphate (S1P) and lysophosphatidic acid LPA) have recently emerged as potentially highly significant physiological and pathophysiological regulators of bone cell biology. Since compromised signaling by these bioactive lipids has been implicated in the etiology of disorders such as inflammatory and autoimmune diseases, their role in bone biology can be a key influence in the coordination of the events underlying osteoimmunology. Both S1P and LPA have been shown to have receptor-mediated effects on osteoblastic cell proliferation and differentiation critical to bone formation and on osteoclastic cell action and regulation of bone resorption. This review of the recent studies on these processes provides insight into the potential role of S1P and LPA as autocrine and paracrine mediators of bone remodeling and their potential interaction with immune cells that have emerged as important players in skeletal biology.
- 5 September 2013
- Published by Taylor & Francis in Immunological Investigations
- Vol. 42 (7) , 510-518
The role of sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) in regulation of osteoclastic and osteoblastic cells
The bioactive lipid molecules, sphingosine-1-phosphate (S1P) and lysophosphatidic acid LPA) have recently emerged as potentially highly significant physiological and pathophysiological regulators of bone cell biology. Since compromised signaling by these bioactive lipids has been implicated in the etiology of disorders such as inflammatory and autoimmune diseases, their role in bone biology can be a key influence in the coordination of the events underlying osteoimmunology. Both S1P and LPA have been shown to have receptor-mediated effects on osteoblastic cell proliferation and differentiation critical to bone formation and on osteoclastic cell action and regulation of bone resorption. This review of the recent studies on these processes provides insight into the potential role of S1P and LPA as autocrine and paracrine mediators of bone remodeling and their potential interaction with immune cells that have emerged as important players in skeletal biology.
- 1 November 2005
- Published by Wiley in Journal of Periodontology
- Vol. 76 (11) , 1833-1841
Platelet‐Derived Growth Factor Enhancement of Two Alloplastic Bone Matrices
Background: The use of alloplastic matrices that mimic the mineral phase of bone has become a viable alternative to current mainstream therapies in dentistry such as allografts and autogenous grafts. Because alloplastic bone substitutes generally have relatively poor osteogenic properties, analyzing their potential as vehicles to deliver growth factors is an important step in assessing methods to enhance their clinical efficacy. The aim of these studies was to treat beta‐tricalcium phosphate (β‐TCP) and calcium sulfate (CaSO4) with platelet‐derived growth factor (PDGF)‐BB to enhance the osteogenic capabilities of these materials.Methods: In the β‐TCP studies, PDGF‐BB adsorption and release were accomplished using 125I radiolabeled growth factor and non‐radioactive human recombinant PDGF at a ratio of 1:300 M. For the adsorption studies, the radiolabeled PDGF‐BB/ non‐radioactive PDGF solutions with resultant PDGF concentrations of 10−7 and 10−8 M were incubated with β‐TCP from 1 to 120 minutes, and the amount of adsorbed 125I‐PDGF‐BB was measured using a gamma counter. Similar adsorption studies were conducted with a 30‐minute incubation of β‐TCP with various PDGF concentrations. In vitro release studies were conducted with β‐TCP to which radiolabeled PDGF had been adsorbed as above. Release studies were also conducted with CaSO4 that was hydrated with the radioactive PDGF solution described above for the TCP studies. In vivo PDGF‐BB release from β‐TCP and CaSO4 was evaluated in a mouse model, where the radioactive PDGF/non‐radioactive PDGF‐BB treated β‐TCP or CaSO4 sample was inserted subcutaneously and later removed for radioactive measurement. Proliferation of human osteoblastic cells in the presence of PDGF‐ treated β‐TCP or CaSO4 was assessed by 3H thymidine incorporation.Results: The absorption studies revealed that PDGF‐BB was absorbed in a concentration and time‐dependent manner to β‐TCP. In the in vitro release studies, ∼45% of the adsorbed PDGF‐BB was released after 10 days. In vivo release from both materials occurred faster than in vitro release. Osteoblastic cells incubated with PDGF‐BB‐treated matrices showed significantly (P Conclusion: These experiments demonstrate the feasibility of using PDGF‐BB in combination with alloplastic materials such as β‐TCP or CaSO4 to serve as more effective bone graft materials with enhanced osteogenic properties.
- 1 November 2005
- Published by Wiley in Journal of Periodontology
- Vol. 76 (11) , 1833-1841
Platelet‐Derived Growth Factor Enhancement of Two Alloplastic Bone Matrices
Background: The use of alloplastic matrices that mimic the mineral phase of bone has become a viable alternative to current mainstream therapies in dentistry such as allografts and autogenous grafts. Because alloplastic bone substitutes generally have relatively poor osteogenic properties, analyzing their potential as vehicles to deliver growth factors is an important step in assessing methods to enhance their clinical efficacy. The aim of these studies was to treat beta‐tricalcium phosphate (β‐TCP) and calcium sulfate (CaSO4) with platelet‐derived growth factor (PDGF)‐BB to enhance the osteogenic capabilities of these materials.Methods: In the β‐TCP studies, PDGF‐BB adsorption and release were accomplished using 125I radiolabeled growth factor and non‐radioactive human recombinant PDGF at a ratio of 1:300 M. For the adsorption studies, the radiolabeled PDGF‐BB/ non‐radioactive PDGF solutions with resultant PDGF concentrations of 10−7 and 10−8 M were incubated with β‐TCP from 1 to 120 minutes, and the amount of adsorbed 125I‐PDGF‐BB was measured using a gamma counter. Similar adsorption studies were conducted with a 30‐minute incubation of β‐TCP with various PDGF concentrations. In vitro release studies were conducted with β‐TCP to which radiolabeled PDGF had been adsorbed as above. Release studies were also conducted with CaSO4 that was hydrated with the radioactive PDGF solution described above for the TCP studies. In vivo PDGF‐BB release from β‐TCP and CaSO4 was evaluated in a mouse model, where the radioactive PDGF/non‐radioactive PDGF‐BB treated β‐TCP or CaSO4 sample was inserted subcutaneously and later removed for radioactive measurement. Proliferation of human osteoblastic cells in the presence of PDGF‐ treated β‐TCP or CaSO4 was assessed by 3H thymidine incorporation.Results: The absorption studies revealed that PDGF‐BB was absorbed in a concentration and time‐dependent manner to β‐TCP. In the in vitro release studies, ∼45% of the adsorbed PDGF‐BB was released after 10 days. In vivo release from both materials occurred faster than in vitro release. Osteoblastic cells incubated with PDGF‐BB‐treated matrices showed significantly (P Conclusion: These experiments demonstrate the feasibility of using PDGF‐BB in combination with alloplastic materials such as β‐TCP or CaSO4 to serve as more effective bone graft materials with enhanced osteogenic properties.
- 1 March 2003
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 68 (3) , 239-249
Effects of sphingosine-1-phosphate and lysophosphatidic acid on human osteoblastic cells
- 1 March 2003
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 68 (3) , 239-249
Effects of sphingosine-1-phosphate and lysophosphatidic acid on human osteoblastic cells